Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …

Objective To develop a new evidence‐based, pharmacologic treatment guideline for
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …

Background Increases in lipid levels and cancers with tofacitinib prompted a trial of major
adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis …

Rheumatoid arthritis (RA) is considered a chronic disease that cannot be cured. Biologic
agents have enabled good therapeutic successes; however, the response to biologic …

The American College of Rheumatology (ACR) most recently published recommendations
for the use of diseasemodifying antirheumatic drugs (DMARDs) and biologic agents in the …

Background Reaching the therapeutic target of remission or low-disease activity has
improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target …

Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there
is no widely used definition of remission that is stringent but achievable and could be …

Background Aiming at therapeutic targets has reduced the risk of organ failure in many
diseases such as diabetes or hypertension. Such targets have not been defined for …

Objectives To define disease activity levels, minimal clinically important improvement (MCII)
and patient-acceptable symptom state (PASS) with the primary Sjögren's syndrome (SS) …

Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral
inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite …